[en] This project was designed to carry out routine production of Ga-68 labeled radiopharmaceuticals for use, particularly in pulmonary studies; to continue work on the development of Ga-68 labeled radiopharmaceuticals that could be used with positron emission tomography; to evaluate indium-111 and possibly gallium-68 labeled antibodies in animal models; to continue development of new chelates and bifunctional chelates for use as radiopharmaceuticals; and to develop new approaches to the delivery of radiopharmaceuticals to the brain. We have made major advances in all of these areas. In area one, we have shown that gallium-68 radiopharmaceuticals can be produced routinely under robotic control for patient studies. This has resulted in several publications by us and by our collaborators in the Pulmonary Division at Washington University. In the second area, we have continued to study gallium-68 labeled radiopharmaceuticals and have carried out the work to allow gallium-68 labeled macroaggregated albumin to be administered to patients. This was necessary due to the fact that our previous gallium-68 particulate tracer, gallium-68 labeled microspheres could not be prepared due to the fact that the microsphere kit from 3M was removed from the market. In the area of labeled antibodies we have studied indium-111 labeled antibodies in two animal models and compared gallium-68 labeled antibodies with indium and iodine antibodies in one of these models. It appears that gallium-68 labeled antibody fragments may have promise as radiopharmaceuticals